A Phase I/II Study to Evaluate the Safety and Efficacy of Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Vinorelbine (Primary)
- Indications Breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 10 Apr 2017 Planned primary completion date changed from 1 Oct 2021 to 1 Jul 2022.